Death in pediatric Cushing syndrome is uncommon but still occurs

Alexandra Gkourogianni1, Maya B Lodish, Mihail Zilbermint

  • 1Section on Endocrinology and Genetics and Pediatric Endocrinology Inter-Institute Training Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health Clinical Research Center, 10 Center Drive, Building 10, Room 1-3330, MSC1103, Bethesda, MD, 20892, USA, alexandragk@med.uoa.gr.

Insights

Pediatric Cushing syndrome (CS) has a 2.5% mortality rate, with sepsis being a primary cause of death. Early recognition and prompt treatment are crucial for managing this rare condition in children.

Area of Science:

  • Pediatric Endocrinology
  • Rare Diseases
  • Clinical Pediatrics

Background:

  • Cushing syndrome (CS) in children is a rare condition.
  • Delayed diagnosis and treatment can lead to significant morbidity and mortality.
  • Recognizing and managing pediatric CS is critical due to its potential severity.

Purpose of the Study:

  • To describe deceased patients among cases of pediatric CS referred to the National Institutes of Health (NIH).
  • To analyze the mortality rate and causes of death in pediatric CS patients.
  • To inform healthcare providers about the risks associated with pediatric CS.

Main Methods:

  • Retrospective review of pediatric CS patients (<18 years) referred to the NIH from 1998-2013.
  • Analysis of demographic data, clinical presentation, causes of CS, and causes of death.
  • Comparison of presenting symptoms and causes of CS in deceased patients versus the overall cohort.

Main Results:

  • Four deaths (2.5% mortality) were recorded among 160 pediatric CS patients.
  • Deceased patients' ages ranged from 7.5-15.5 years, with disease duration of 2-4 years.
  • Causes of death included sepsis (three patients) and residual disease/complications (one patient).
  • Causes of CS in deceased patients included pituitary disease, ectopic ACTH production, and adrenal hyperplasia.
  • Presenting symptoms and causes of CS did not differ between deceased and surviving patients.

Conclusions:

  • A 2.5% mortality rate was observed in pediatric CS patients referred to a tertiary care center.
  • Sepsis is a significant cause of mortality in pediatric CS.
  • Pediatricians must be aware of the potential for mortality in pediatric CS and manage patients accordingly.
Abstract

Related Concept Videos

Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features...
9
Cushing Syndrome I: Introduction01:26

Cushing Syndrome I: Introduction

Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the...
16
Adrenal Gland Disorders01:27

Adrenal Gland Disorders

Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
3.6K
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show...
53
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
398
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
394